115372 Results

People

  1. Ladanyi
    Ladanyi
  2. Motzer
    Motzer
  3. Reuter
    Reuter
  4. Scher
    Scher
  5. Brennan
    Brennan
  6. Giralt
    Giralt
  7. Gonen
    Gonen
  8. Perales
    Perales
  9. Hudis
    Hudis
  10. Jarnagin
    Jarnagin

Groups

  1. Department of Medicine (39034)
  2. GSK Faculty (22468)
  3. Solid Tumor Oncology Division (22057)
  4. Surgery (21249)
  5. Sloan Kettering Institute Faculty (16086)
  6. Survivorship Research (15763)
  7. Center for Hematologic Malignancies (13263)
  8. Hematologic Malignancies, Division of (13087)
  9. Sloan Kettering Institute Postdocs (12936)
  10. Department of Pathology and Laboratory Medicine (12615)
Formats
  1. Journal Article (66748)
  2. Meeting Abstract (33620)
  3. Book Section (5027)
  4. Review (3743)
  5. Editorial (2162)
  6. Conference Paper (1525)
  7. Correspondence (661)
  8. Guidelines (661)
  9. Research Letter (548)
  10. Miscellaneous (339)
  11. Book Whole (338)
Groups
  1. Department of Medicine (39034)
  2. GSK Faculty (22468)
  3. Solid Tumor Oncology Division (22057)
  4. Surgery (21249)
  5. Sloan Kettering Institute Faculty (16086)
  6. Survivorship Research (15763)

More Groups

People
  1. Marc Ladanyi (1327)
  2. Robert Motzer (1243)
  3. Victor Reuter (1228)
  4. Howard Scher (1130)
  5. Murray Brennan (1059)
  6. Sergio Giralt (1050)

More People

Years
  1. 2025 (1982)
  2. 2024 (5377)
  3. 2023 (5804)
  4. 2022 (6168)
  5. 2021 (5712)
  6. 2020 (5599)

More Years

Publications
  1. Journal of Clinical Oncology (8590)
  2. Blood (4950)
  3. Cancer Research (2701)
  4. International Journal of Radiation Oncology, Biology, Physics (2610)
  5. Laboratory Investigation (1879)
  6. Modern Pathology (1812)

More Publications

Publishers
  1. Elsevier Inc. (13855)
  2. American Society of Clinical Oncology (9157)
  3. Springer (7152)
  4. Nature Publishing Group (6367)
  5. American Association for Cancer Research (6002)
  6. Elsevier Science, Inc. (5503)

More Publishers

Results (115372)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Activity of larotrectinib in TRK fusion lung cancer
    Meeting Abstract

    Drilon, A.; Kummar, S.; Moreno, V.; Patel, J.; Lassen, U.; Rosen, L.; Childs, B. H.; Nanda, S.; Cox, M. C.; Ku, N. C.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • KEYNOTE-811 pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction cancer: A double-blind, randomized, placebo-controlled phase 3 study
    Meeting Abstract

    Chung, H.; Bang, Y.; Fuchs, C.; Qin, S.; Satoh, T.; Shitara, K.; Tabernero, J.; Van Cutsem, E.; Cao, Z.; Chen, X.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Comparative analyses between younger and older patients with pancreatic adenocarcinoma: Differences in clinicopathological features, treatment patterns, and outcomes
    Meeting Abstract

    Salem, M.; Kadakia, K.; Trufan, S.; Hwang, J.; Nazemzadeh, R.; Jagosky, M.; Worrilow, W.; Coley, H.; Al Hallak, M.; Gower, N.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Entrectinib in locally advanced or metastatic ROS1 fusion-positive non-small cell lung cancer (NSCLC): Integrated analysis of ALKA-372-001, STARTRK-1 and STARTRK-2
    Meeting Abstract

    Barlesi, F.; Drilon, A.; De Braud, F.; Cho, B. C.; Ahn, M. J.; Siena, S.; Krebs, M. G.; Lin, C. C.; John, T.; Tan, D. S. W.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • An international, randomized, open-label, phase III trial of adjuvant nab-paclitaxel plus gemcitabine vs gemcitabine alone for surgically resected pancreatic adenocarcinoma (APACT): Primary analysis and quality of life outcomes
    Meeting Abstract

    Reni, M.; Riess, H.; O'Reilly, E.; Santoro, A.; Park, J.; Bekaii-Saab, T.; Tempero, M.; Shan, Y.; Macarulla, T.; Van Cutsem, E.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Analysis of patient screening in the phase III, international, randomized, open-label APACT trial
    Meeting Abstract

    Reni, M.; Winter, J.; Tortora, G.; Pelzer, U.; Riess, H.; Chang, H.; O'Reilly, E.; Oh, D.; Diaz, I. A.; Milella, M.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Treating HER2-mutant advanced biliary tract cancer with neratinib: Benefits of HER2-directed targeted therapy in the phase 2 SUMMIT 'basket; trial
    Meeting Abstract

    Harding, J.; Cleary, J.; Shapiro, G.; Braña, I.; Moreno, V.; Quinn, D.; Borad, M.; Loi, S.; Spanggaard, I.; Stemmer, S.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • BEACON CRC: A randomized, 3-Arm, phase 3 study of encorafenib and cetuximab with or without binimetinib vs. choice of either irinotecan or FOLFIRI plus cetuximab in BRAF V600E-mutant metastatic colorectal cancer
    Meeting Abstract

    Kopetz, S.; Grothey, A.; Van Cutsem, E.; Yaeger, R.; Wasan, H.; Yoshino, T.; Desai, J.; Ciardiello, F.; Gollerkeri, F.; Maharry, K.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Debio 1347 in patients with gastrointestinal cancers harboring an FGFR gene fusion: Preliminary results
    Meeting Abstract

    Matos, I.; Goyal, L.; Cleary, J.; Voss, M.; Oh, D.; Bernstam, F. M.; Ng, C.; Iyer, G.; Ishii, N.; Hu, Y.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Olaparib as maintenance treatment following first-line platinum-based chemotherapy in patients with a germline BRCA mutation and metastatic pancreatic cancer: Phase III POLO trial
    Meeting Abstract

    Golan, T.; Hammel, P.; Reni, M.; Van Cutsen, E.; Macarulla, T.; Hall, M.; Park, J.; Hochhauser, D.; Arnold, D.; Oh, D.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save